Growth Factors (Blood and Tissue) Market 2014 - Global Strategic Business Report
M2 - 1 hr 38 mins ago
Research and Markets (http://www.researchandmarkets.com/research/bqzzts/growth_factors) has announced the addition of the "Growth Factors (Blood and Tissue) - Global Strategic Business Report" report to their offering. The report provides separate comprehensive analytics for the US, Canada, Japan, Europe, Asia-Pacific, and Rest of World. Annual estimates and forecasts are provided for the period 2013 through 2020. Also, a seven-year historic analysis is provided for these markets. Market data and analytics are derived from primary and secondary research. This report analyzes the worldwide markets for Growth Factors (Blood and Tissue) in US$ Million by the following Types: - Blood Growth Factors (Erythropoietins, Colony Stimulating Factors, Interferons, & Interleukins) - Tissue Growth Factors. The report profiles 90 companies including many key and niche players such as: - Alseres Pharmaceuticals, Inc. - Amgen, Inc. - Bayer HealthCare Pharmaceuticals, Inc. - Biogen Idec Inc - BioMimetic Therapeutics, Inc. - Biopharm GmbH - Bolder Biotechnology, Inc. - F. Hoffmann-La Roche Ltd - Chugai Pharmaceutical Co. Ltd. - Genentech, Inc. - FibroGen, Inc. - Johnson & Johnson - Janssen Biotech, Inc. - Lonza Group - Merck Serono International S.A. - NsGene A/S - PeproTech, Inc. - Reliance GeneMedix Plc - Sangamo BioSciences, Inc. - Sanofi - Shantha Biotechnics - Scil Proteins GmbH - Wockhardt Ltd. Key Topics Covered: I. Introduction, Methodology & Product Definitions II. Executive Summary 1. Market Overview 2. Growth Factors An Overview 3. Research Studies & Clinical Trials 4. Product Innovations/Introductions 5. Recent Industry Activity 6. Focus On Select Players 7. Global Market Perspective III. Market 1. The United States 2. Canada 3. Japan 4. Europe 5. Asia-Pacific 6. Rest Of World IV. Competitive Landscape Total Companies Profiled: 90 (including Divisions/Subsidiaries 95) - The United States (42) - Japan (
Why Amgen, Inc.’s Kyprolis FOCUS Failure Is a Big Deal
Brian Orelli, The Motley Fool - Motley Fool - Wed Aug 13, 7:52PM CDT
Source: Amgen Amgen 's Kyprolis has passed multiple clinical trials, but the failure today will overshadow the rest. That's because the only thing that really matters to cancer patients is survival. Does the drug help the patient live longer?...
AMGEN
at Investor's Business Daily - Wed Aug 13, 5:58PM CDT
AMGEN (AMGN) fell 2.1% in late trading after its Onyx subsidiary announced disappointing results from a late-stage trial of skin-cancer treatment Kyprolis vs. standard treatment.
Final Glance: Biotechnology companies
AP - Wed Aug 13, 5:14PM CDT
NEW YORK (AP) — Shares of some top biotechnology companies were up at the close of trading:
Amgen Issues Voluntary Recall of Aranesp® (darbepoetin alfa) (500 mcg) Prefilled Syringes in Several Countries Outside of the United States Due to the Presence of Visible Particulates
PR Newswire - Wed Aug 13, 3:12PM CDT
Amgen (NASDAQ:AMGN) initiated a voluntary recall on June 26, 2014 for nine packaged lots of Aranesp® (darbepoetin alfa) (500 mcg) prefilled syringes from non-U.S. distributors, wholesalers and a number of hospital pharmacies due to the potential presence of cellulose and/or polyester particles observed in a small number of syringes during a routine quality examination. Lots 1042847, 1044141A, 1044141C, 1044141D, 1046891A, 1046891B, 1047394A, 1047622A, and 1047996A are being recalled as a precautionary measure. To date, there have been no complaints or adverse events reported that can be attributed to the presence of these particles. Evaluations by Amgen found a very low potential to impact patients who may have received the affected product.
Amgen Announces Top-Line Results From Phase 3 Focus Trial Of Kyprolis® In Patients With Relapsed And Advanced Refractory Multiple Myeloma
PR Newswire - Wed Aug 13, 3:01PM CDT
Amgen (NASDAQ:AMGN) and its subsidiary, Onyx Pharmaceuticals, Inc., today announced that the Phase 3 clinical trial FOCUS (CarFilzOmib for AdvanCed Refractory MUltiple Myeloma European Study) did not meet its primary endpoint of improving overall survival (OS) (HR=0.975, 95 percent CI, 0.760, 1.249). The 315-patient, open-label study evaluated single-agent Kyprolis® (carfilzomib) for Injection compared to an active control regimen of low-dose dexamethasone, or equivalent corticosteroids, plus optional cyclophosphamide in patients with relapsed and advanced refractory multiple myeloma. Nearly all patients in the control arm received cyclophosphamide. Patients were heavily pretreated and had received a median of five therapeutic regimens prior to study entry.
Midday Glance: Biotechnology companies
AP - Wed Aug 13, 12:50PM CDT
NEW YORK (AP) — Shares of some top biotechnology companies are up at 1 p.m.:
Early Glance: Biotechnology companies
AP - Wed Aug 13, 9:32AM CDT
NEW YORK (AP) — Shares of some top biotechnology companies are up at 10 a.m.:
UBS AG Contemplates $4.5B Bond Offerings in U.S. - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Aug 12, 4:05PM CDT
As per Bloomberg, the Swiss major UBS AG (UBS) is planning corporate bond offerings in the U.S. The bank will be issuing $4.5 billion worth of bonds.
Biological Drugs Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2014 - 2020
PR Newswire Europe - Tue Aug 12, 12:50PM CDT
DUBLIN, Aug. 12, 2014 /PRNewswire/ -- Research and Markets [http://www.researchandmarkets.com/research/kpr76z/biological_drugs] has announced the addition of the "Biological Drugs Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2014 - 2020" [http://www.researchandmarkets.com/research/kpr76z/biological_drugs] report to their offering.
Amgen Up 8.6% Since SmarTrend Uptrend Call (AMGN)
Comtex SmarTrend(R) - Tue Aug 12, 9:27AM CDT
SmarTrend identified an Uptrend for Amgen (NASDAQ:AMGN) on June 2nd, 2014 at $116.45. In approximately 2 months, Amgen has returned 8.57% as of today's recent price of $126.43.
5 Things Amgen, Inc.'s Management Wants You to Know
Sean Williams, The Motley Fool - Motley Fool - Mon Aug 11, 3:25PM CDT
Amgen reported its second-quarter earnings results two weeks ago, delivering yet another quarter of impressive growth and boosting full-year guidance. Source: University of Michigan School of Natural Resources & Environment , Flickr. ...
Investors Applaud Amgen and Novartis for Support of Investor Principles on Biosimilars, Alternatives to Higher Cost Drugs
PR Newswire - Mon Aug 11, 12:07PM CDT
A coalition of 19 institutional investors representing $430 billion in assets commends Amgen and Novartis for support of a set of investor principles to guide corporate boards on policy and oversight responsibilities related to biosimilar activities. The principles, included in the coalition's Investor Statement on Board Oversight of Biosimilar Issues, call on boards to ensure that information provided to policymakers on patient safety is balanced, investor dollars used for political lobbying is aligned with shareholder interests, and disclosure on significant business partnerships is transparent. Biosimilars are biologic medical products whose active drug substance is derived from a living organism and used to treat serious illnesses including cancer, rheumatoid arthritis, and multiple sclerosis.
Earnings Flashback: Since Reporting Quarterly Results 1 Week Ago Amgen Is Up 3.0% (AMGN)
Comtex SmarTrend(R) - Mon Aug 11, 12:02PM CDT
A week ago on July 29th, 2014 Amgen (NASDAQ:AMGN) reported earnings and analysts, on average, expected earnings of $2.07 on sales of $4.9 billion. The company actually reported EPS of $2.37 on sales of $5.2 billion, beating EPS estimates by $0.30 and beating revenue estimates by $279.7 million. Shares of Amgen have climbed from $123.31 to $126.95, representing a gain of 3.0% since the company reported earnings 13 days ago.
Amgen Receives CEO Cancer Gold Standard Accreditation
Business Wire - Mon Aug 11, 6:00AM CDT
The CEO Roundtable on Cancer today announced that Amgen, Inc., one of the world's leading biotechnology companies, has received CEO Cancer Gold Standard(TM) accreditation. This achievement recognizes employers' commitment to reducing cancer risk by promoting healthy lifestyle choices, encouraging early detection through cancer screenings, and ensuring access to quality treatment for employees and covered family members.
Jim Cramer's 'Mad Money' Recap: Next Week's Game Plan
at The Street - Fri Aug 08, 7:15PM CDT
Cramer's watching earnings next week as he seeks stocks worth buying, not selling, in this market.